PhRMA: resetting the conversation
Over the last few years, the issue of drug prices has been rising ever higher on the agenda in the US. Prominent politicians, including former democratic presidential hopeful and champion of American socialism Bernie Sanders, have campaigned hard to bring predatory pricing by pharmaceutical companies into the public eye.
Do healthcare cuts risk creating a ‘desert for innovation’ in the UK?
The world’s biggest drug companies could reconsider their operations in the UK if the country’s new Government doesn’t increase its spending on NHS treatments and patient access to new medicines, according to the Association of the British Pharmaceutical Industry (ABPI).
Betting big on Gamma Delta T Cells
Gamma Delta T Cells live in our tissue and form a crucial part of our immune system. Until recently, they have been on the sidelines of cancer research, but a $100m cash injection from drug giant Takeda Pharmaceuticals into a small biotech firm with big ideas in this area is set to change that, bringing a new class of immunotherapies one step closer to reality.
Pharma Technology Focus – Issue 61
In this issue: The UK’s healthcare spending problem, PhRMA’s new R&D spending requirements, undermining supply chain security by importing foreign drugs, milestone cystic fibrosis trials, a personalised treatment approach for panic disorder, and more.
Cystic fibrosis: searching for a breakthrough
There are exciting years ahead for the treatment of cystic fibrosis (CF). This inherited autosomal recessive genetic disorder has proven to be incredibly tough for drug developers, with research efforts hampered by the formidable scientific challenges involved.